Trial Outcomes & Findings for Use of Pediatric Size Phlebotomy Tubes in Adult Critically Ill Patients to Reduce Red Blood Cell Transfusions (NCT NCT03286465)
NCT ID: NCT03286465
Last Updated: 2021-08-30
Results Overview
COMPLETED
NA
200 participants
from time of admission to intensive care unit (ICU) to 30 days after admission to ICU
2021-08-30
Participant Flow
Participant milestones
| Measure |
Pediatric Phlebotomy Tubes
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
Overall Study
STARTED
|
100
|
100
|
|
Overall Study
COMPLETED
|
100
|
100
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Use of Pediatric Size Phlebotomy Tubes in Adult Critically Ill Patients to Reduce Red Blood Cell Transfusions
Baseline characteristics by cohort
| Measure |
Pediatric Phlebotomy Tubes
n=100 Participants
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
n=100 Participants
Use of adult size tubes for diagnostic blood collection.
|
Total
n=200 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
55 years
STANDARD_DEVIATION 16.7 • n=5 Participants
|
57 years
STANDARD_DEVIATION 18.5 • n=7 Participants
|
56.2 years
STANDARD_DEVIATION 17.9 • n=5 Participants
|
|
Sex: Female, Male
Female
|
45 Participants
n=5 Participants
|
51 Participants
n=7 Participants
|
96 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
55 Participants
n=5 Participants
|
49 Participants
n=7 Participants
|
104 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Black
|
36 Participants
n=5 Participants
|
46 Participants
n=7 Participants
|
82 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White
|
38 Participants
n=5 Participants
|
39 Participants
n=7 Participants
|
77 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Other
|
26 Participants
n=5 Participants
|
15 Participants
n=7 Participants
|
41 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
100 Participants
n=5 Participants
|
100 Participants
n=7 Participants
|
200 Participants
n=5 Participants
|
|
Hemoglobin concentration at intensive care unit (ICU) admission
|
11.4 g/dL
STANDARD_DEVIATION 2.4 • n=5 Participants
|
11.1 g/dL
STANDARD_DEVIATION 2.3 • n=7 Participants
|
11.24 g/dL
STANDARD_DEVIATION 2.35 • n=5 Participants
|
|
Time from ICU admission to randomization
|
5.3 hours
n=5 Participants
|
5.7 hours
n=7 Participants
|
5.64 hours
n=5 Participants
|
|
Estimated blood volume
|
4.9 liters
n=5 Participants
|
4.6 liters
n=7 Participants
|
4.77 liters
n=5 Participants
|
|
Number of participants with chronic hemodialysis
|
12 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
24 Participants
n=5 Participants
|
|
Number of participants with chronic kidney disease but no dialysis
|
13 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
24 Participants
n=5 Participants
|
|
Number of participants with active malignancy
|
5 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
|
Number of participants with recent history of anemia
|
45 Participants
n=5 Participants
|
47 Participants
n=7 Participants
|
92 Participants
n=5 Participants
|
|
Charlson comorbidity index
|
3.0 score on a scale
n=5 Participants
|
4.0 score on a scale
n=7 Participants
|
3 score on a scale
n=5 Participants
|
|
ICU Admission Diagnosis
Infection
|
55 Participants
n=5 Participants
|
46 Participants
n=7 Participants
|
101 Participants
n=5 Participants
|
|
ICU Admission Diagnosis
Acute Cardiovascular Disorder
|
21 Participants
n=5 Participants
|
24 Participants
n=7 Participants
|
45 Participants
n=5 Participants
|
|
ICU Admission Diagnosis
Acute renal failure
|
40 Participants
n=5 Participants
|
31 Participants
n=7 Participants
|
71 Participants
n=5 Participants
|
|
ICU Admission Diagnosis
Metabolic disorder
|
32 Participants
n=5 Participants
|
36 Participants
n=7 Participants
|
68 Participants
n=5 Participants
|
|
ICU Admission Diagnosis
Non-infectious inflammatory disorder
|
19 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
30 Participants
n=5 Participants
|
|
ICU Admission Diagnosis
Other
|
22 Participants
n=5 Participants
|
31 Participants
n=7 Participants
|
53 Participants
n=5 Participants
|
|
Number of participants who had invasive mechanical ventilation
|
50 Participants
n=5 Participants
|
51 Participants
n=7 Participants
|
101 Participants
n=5 Participants
|
|
APACHE II score
|
22.0 score on a scale
n=5 Participants
|
23.0 score on a scale
n=7 Participants
|
22 score on a scale
n=5 Participants
|
PRIMARY outcome
Timeframe: from time of admission to intensive care unit (ICU) to 30 days after admission to ICUOutcome measures
| Measure |
Pediatric Phlebotomy Tubes
n=100 Participants
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
n=100 Participants
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
Number of Participants Who Had Hemoglobin Less Than 7 g/dL or Red Blood Cell (RBC) Transfusion Order
|
6 Participants
|
11 Participants
|
SECONDARY outcome
Timeframe: from time of randomization to completion of study (up to 30 days after ICU admission)This will be calculated as the most recent hemoglobin prior to randomization minus the last hemoglobin prior to ICU discharge, death, RBC transfusion, clinical bleeding, surgery, or change of clinical status to comfort measures, divided by the number of days (rounded to the nearest 0.5) between these two values (crude estimate).
Outcome measures
| Measure |
Pediatric Phlebotomy Tubes
n=100 Participants
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
n=100 Participants
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
Rate of Change in Hemoglobin (g/dL/Day) While in the Intensive Care Unit (ICU)
|
-0.21 g/dL/day
Interval -0.48 to 0.021
|
-0.2 g/dL/day
Interval -0.54 to 0.038
|
SECONDARY outcome
Timeframe: completion of study (up to 30 days after ICU admission)Outcome measures
| Measure |
Pediatric Phlebotomy Tubes
n=100 Participants
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
n=100 Participants
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
Number of Participants Who Received a Red Blood Cell (RBC) Transfusion While in the ICU
|
4 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: completion of study (up to 30 days after ICU admission)Population: This outcome data was not collected in the arm using adult phlebotomy tubes.
An inadequate blood sample is defined as any blood sample that requires recollection.
Outcome measures
| Measure |
Pediatric Phlebotomy Tubes
n=100 Participants
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
Number of Participants With at Least One Inadequate Blood Sample for Laboratory Analysis
|
7 Participants
|
—
|
SECONDARY outcome
Timeframe: completion of study (up to 30 days after ICU admission)Outcome measures
| Measure |
Pediatric Phlebotomy Tubes
n=100 Participants
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
n=100 Participants
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
ICU Mortality
|
9 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: completion of study (up to 30 days after ICU admission)The total phlebotomy volume is the total volume of blood collected over all days and is estimated based on the maximum volume needed for each type of blood test, as follows. In the pediatric tube arm, the volumes were 0.5 milliliters (mL) for hematology, 0.6 mL for chemistries (plasma), and 2.5 mL for coagulation tests. In the adult tube group, the volumes were 5.5 mL for hematology, 5 mL for chemistries (plasma), and 3.8 mL for coagulation. In both arms, tube volumes for lactate, immunology (serum), arterial blood gases, and blood cultures were 5 mL, 6.5 mL, 1 mL, and 10 mL, respectively.
Outcome measures
| Measure |
Pediatric Phlebotomy Tubes
n=100 Participants
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
n=100 Participants
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
Total Phlebotomy Volume
|
21 mL
Interval 7.0 to 38.0
|
50 mL
Interval 27.0 to 100.0
|
Adverse Events
Pediatric Phlebotomy Tubes
Adult Phlebotomy Tubes
Serious adverse events
| Measure |
Pediatric Phlebotomy Tubes
n=100 participants at risk
Use of pediatric size tubes for diagnostic blood collection.
|
Adult Phlebotomy Tubes
n=100 participants at risk
Use of adult size tubes for diagnostic blood collection.
|
|---|---|---|
|
General disorders
death
|
9.0%
9/100 • Number of events 9 • time of randomization to completion of study (up to 30 days after ICU admission)
Systematically assessed for RBC transfusion-related adverse events.
|
10.0%
10/100 • Number of events 10 • time of randomization to completion of study (up to 30 days after ICU admission)
Systematically assessed for RBC transfusion-related adverse events.
|
Other adverse events
Adverse event data not reported
Additional Information
Javier Barreda Garcia, MD
The University of Texas Health Science Center at Houston
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place